

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 015280-290100US

Assistant Commissioner for Patents
Washington, D.C. 20231

On May 24, 1999

TOWNSEND and TOWNSEND and CREW LLP

By: Jennifer K. Huder

JC978 U.S. PTO
09/853530
05/05/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Klimpel *et al.*

Application No.: 08/937,276

Filed: September 15, 1997

For: TARGETING ANTIGENS TO THE
MHC CLASS I PROCESSING
PATHWAY WITH AN ANTHRAX
TOXIN FUSION PROTEIN

Examiner: Lubet, Martha T.

Art Unit: 1644

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

Box SEQUENCE

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Communication mailed November 23, 1998, Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

IN THE SPECIFICATION:

On page 12, line 28, delete "(SEQ ID NOS: 1 and 2)".

On page 12, line 29, delete "(SEQ ID NOS: 3 and 4)".

On page 12, line 30, replace "(SEQ ID NOS: 5-8)" with "--(SEQ ID NOS:1-4)--".

Express Mail No.
EL 827035141 US